1. Medtech Insight
  2. >>Archive

Recalled ICD Leads Can Be Extracted Safely, Cleveland Clinic Study Shows

A 10-year retrospective study from the Cleveland Clinic shows that implantable cardioverter defibrillator leads subject to recalls can be extracted with the same safety and efficacy as non-recalled ICD leads. Another study, published in the same issue of Heart Rhythm, found that younger age and female sex are independent predictors of failure for St. Jude’s Riata lead.

St. Jude Medical Inc.’s Riata and Medtronic PLC’s Sprint Fidelis implantable cardioverter defibrillator leads, both subject to major recalls, can be extracted from patients’ hearts as easily as non-recalled leads, a major 10-year retrospective study at the Cleveland Clinic suggests.

Medtronic initiated a class I recall of Sprint Fidelis leads in 2007 after adverse event reports showed they were prone to conductor fracture that may cause inappropriate shocks and loss...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.